在年龄相关性黄斑变性治疗对照试验 (Comparison of Age-related Macular Degeneration Treatment Trials [CATT]) 第2年结果分析中, Sharma (p. 865) 等对视力 (visual acuity [VA]) 和眼底照片 (fundus photography [FP]) 、荧光素血管造影 (fluorescein angiography [FA]) 、光学相干断层扫描 (optical coherence tomography [OCT]) 等形态学特征的相关性进行了描述。研究者发现这项前瞻性随机研究中, 第1年随访中观察到VA和形态学特征的相关性在第2年随访中得到保持或增强。经过2年玻璃体腔注射治疗后, 视力最差者见于具备以下特征患眼:OCT显示残留中心凹视网膜层间积液、视网膜异常变薄、增厚的视网膜下组织复合体、或FP/FA示中心凹下地图样萎缩或瘢痕形成。反之, 中心凹视网膜下积液与较好VA相关。在1185名CATT受试者中, 993 (84%) 人基线时OCT见积液并完成了2年随访。

The authors of “Vasodilators, Blood Pressure-Lowering Medications, and Age-Related Macular Degeneration: The Beaver Dam Eye Study” (Ophthalmology 2014;121:1604-11) wish to make the following correction to their paper:

En un análisis del segundo año de la Comparación de Estudios de Tratamiento de Degeneración Macular Relacionada con la Edad (CATT), Sharma y otros (p. 865) describieron la asociación entre la agudeza visual (VA) y las características morfológicas de la fotografía del fondo de ojo (FP), la angiografía con fluoresceína (FA) y la tomografía de coherencia óptica (OCT). Encontraron que la asociación entre la VA y las características morfológicas identificadas durante el primer año de este estudio prospectivo, aleatorio se mantuvieron o se fortalecieron durante el segundo año.

We read with interest the article “Decreased corneal sensation and subbasal nerve density, and thinned corneal epithelium as a result of 360-degree laser retinopexy” by Bouheraoua et al.1 The authors discuss the effects of dense circumferential laser retinopexy on corneal nerves and esthesiometry by comparing patients operated for retinal detachment versus macular hole. There may be a few differences in the groups that should be considered.

We thank Dr. Kaufman for his interest in our paper. Dr. Kaufman thinks our results are overstated and the reported relationship is trivial. We disagree and would like to respond to his comments.

I read “Diabetic macular edema: pathophysiology and novel therapeutic targets” published July 2015 by Das et al. This article is interesting because it outlines the role that inflammation plays in the pathogenesis of diabetic macular edema (DME) and discusses the novel therapies in this disease area. Das et al refer to the efficacy and safety of the fluocinolone acetonide (FAc) implant (ILUVIEN), which is licensed for the treatment of DME in a number of European countries and the United States. However, the authors do not present the data relating to ILUVIEN specifically (with a release rate of 0.2 μg FAc per day1), nor do they outline the differences between licensed indications in Europe and the United States.